IPSC CENTURY THERAPEUTICS INC

Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced that members of the management team will participate in the following events at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024:

  • Autoimmune Disease Cell Therapy Panel: 3:00 PM ET
    • Presenter: Chad Cowan, Ph.D., Chief Scientific Officer
  • Fireside Chat: 4:30 PM ET
    • Presenters: Brent Pfeiffenberger, Pharm.D., Chief Executive Officer, and Chad Cowan, Ph.D., Chief Scientific Officer

A live webcast of the fireside chat can be accessed on the “Events & Presentations” page in the “Investors” section of the Company’s website at . A replay of the webcast will be available for 90 days following the event.

About Century Therapeutics

Century Therapeutics (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer and autoimmune diseases that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived cell product candidates are designed to specifically target hematologic and solid tumor cancers, with a broadening application to autoimmune diseases. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer and autoimmune disease care. For more information on Century Therapeutics please visit .

For More Information:

Investor Relations & Media Contacts

Century Therapeutics

Katja Buhrer

SVP, Head of Corporate Affairs and Strategy

 

917-969-3438

Argot Partners

Noor Pahlavi

 

212-600-1902



EN
26/11/2024

Underlying

IPSCCENTURY THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CENTURY THERAPEUTICS INC

 PRESS RELEASE
Free
IPSC CENTURY THERAPE...

Century Therapeutics to Participate in Upcoming Investor Conferences i...

Century Therapeutics to Participate in Upcoming Investor Conferences in March PHILADELPHIA, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today announced that the company will participate in the following upcoming investor conferences in March: TD Cowen 46th Annual Health Care Conference: Fireside chat at 9:50 a.m. ET on Wednesday, March 4, 2026, in Boston, MA. Leerink Partners Global Healt...

February 25, 2026 1 EN
 PRESS RELEASE
Free
IPSC CENTURY THERAPE...

Century Therapeutics Secures Oversubscribed $135 Million Private Place...

Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes PHILADELPHIA, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced it has entered into a securities purchase agreement for a private placement for initial gross proceeds of approximately $135 million to the Company, before placement agent fee...

January 8, 2026 1 EN
 PRESS RELEASE
Free
IPSC CENTURY THERAPE...

Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. H...

Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors PHILADELPHIA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced the appointments of Han Lee, Ph.D., M.B.A., and Martin Murphy, Ph.D., to its Board of Directors. As part of their appointments, Dr. Lee will serve as a member of the Audit and the Compensation Committees and Dr. Murphy will s...

December 9, 2025 1 EN
 PRESS RELEASE
Free
IPSC CENTURY THERAPE...

Century Therapeutics to Participate in Piper Sandler 37th Annual Healt...

Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference PHILADELPHIA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced that the company will participate in the Piper Sandler 37th Annual Healthcare Conference in New York, NY, as follows: Chad Cowan, Ph.D., Chief Scientific Officer of Century Therapeutics, will participate in the “State of the Art in Cell Therapy” panel discus...

November 25, 2025 1 EN
 PRESS RELEASE
Free
IPSC CENTURY THERAPE...

Century Therapeutics Reports Third Quarter 2025 Financial Results and ...

Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update Announced iPSC derived beta islet cell program for Type 1 diabetes (T1D); Investigational New Drug (IND)-enabling studies expected to initiate by year-end 2025; IND submission planned in 2026CNTY-308 advancing through IND-enabling studies to support planned clinical study initiation in 2026Estimated cash runway into 4Q 2027 PHILADELPHIA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)...

November 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch